Dr. Reddy's Laboratories Limited (RDY) Balance Sheet

The balance sheet has expanded rapidly, with total assets rising from $387.5B to $575.3B over ten quarters, a 48% increase. This growth was fueled by a surge in total debt from $20.0B to $72.0B, while equity grew more modestly from $280.6B to $383.4B. The rising leverage, with D/E climbing from 0.07 to 0.19, suggests the company is financing its expansion through borrowing rather than internal cash generation, which appears inconsistent with the deteriorating operating margins reported in the income statement.

Total debt increased from $20.0B in 2024Q4 to $72.0B in 2027Q1, a 260% jump, while equity grew only 37%. The D/E ratio, though still low at 0.19, has tripled, indicating a deliberate move to use debt for acquisitions and capital expenditure, as seen in the cash flow statement's net acquisition outflows. This leverage appears manageable given the company's cash balance of $11.2B and strong asset base, but the rapid pace of debt accumulation warrants monitoring, especially if operating cash flow remains negative as in 2027Q1.

The asset mix reveals a growing emphasis on tangible assets, with PPE net increasing 50% over the period, consistent with the surge in capital expenditure noted in the cash flow analysis. Goodwill also tripled from $4.3B to $12.9B, reflecting acquisition activity, which introduces impairment risk if acquired businesses underperform. The rising proportion of fixed assets suggests a more asset-heavy model, which could strain returns if the expected revenue from complex generics and biosimilars does not materialize.

Equity quality appears solid, with retained earnings accounting for the bulk of the increase, rising from $265.3B to $356.4B. This suggests the company is reinvesting profits rather than distributing them, which aligns with its conservative dividend policy. However, the recent net income decline to $4.5B in 2027Q1, per income statement data, may slow future retained earnings growth, and the lack of significant share repurchases or dilution suggests a stable share count.

The current ratio has declined from 2.58 in 2024Q4 to 1.90 in 2027Q1, indicating a tighter liquidity position. Cash balances have been volatile, peaking at $18.7B in 2026Q3 but falling to $11.2B by 2027Q1, which, combined with negative operating cash flow of -$927M in that quarter, suggests the company may be relying on debt to fund operations. The current ratio remains above 1.5, providing some cushion, but the trend is concerning given the working capital drain identified in the cash flow analysis.